Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
First Claim
1. A method for the administration of a therapeutic amount of a growth factor protein formulation in the treatment of a patient displaying symptoms of acute coronary artery disease comprising the steps of:
- a) administering by inhalation thereby at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising;
1. a growth factor protein selected from the group consisting of FGF-1 and FGF-2, and mixtures thereof, and2. PIGF;
b) monitoring one or more clinical indicators of acute coronary artery disease;
c) determining, based on monitoring the one or more clinical indicators of coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is indicated;
d) depending on the results of step c), administering one or more additional doses of a second growth factor protein formulation comprising;
1. a growth factor protein being selected from the group consisting of FGF-1 and FGF-2, and mixtures thereof, and2. PIGF; and
e) repeating steps b) through d) until there is a clinical indication of amelioration of the symptoms of acute coronary artery disease in the patient, or until there is a contraindication to continued treatment.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.
32 Citations
8 Claims
-
1. A method for the administration of a therapeutic amount of a growth factor protein formulation in the treatment of a patient displaying symptoms of acute coronary artery disease comprising the steps of:
-
a) administering by inhalation thereby at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising; 1. a growth factor protein selected from the group consisting of FGF-1 and FGF-2, and mixtures thereof, and 2. PIGF; b) monitoring one or more clinical indicators of acute coronary artery disease; c) determining, based on monitoring the one or more clinical indicators of coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is indicated; d) depending on the results of step c), administering one or more additional doses of a second growth factor protein formulation comprising; 1. a growth factor protein being selected from the group consisting of FGF-1 and FGF-2, and mixtures thereof, and 2. PIGF; and e) repeating steps b) through d) until there is a clinical indication of amelioration of the symptoms of acute coronary artery disease in the patient, or until there is a contraindication to continued treatment. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A method for the administration of a therapeutic amount of a growth factor protein formulation in the treatment of a patient displaying symptoms of chronic coronary artery disease comprising the steps of:
-
a) administering by inhalation therapy at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising; 1. a growth factor protein selected from the group consisting of FGF-1 and FGF-2, and mixtures thereof, and 2. PIGF; b) monitoring one or more clinical indicators of chronic coronary artery disease; c) determining, based on monitoring the one or more clinical indicators of chronic coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is indicated; d) depending on the results of step c), administering one or more additional doses of a second growth factor protein formulation comprising; 1. a growth factor protein being selected from the group consisting of FGF1 and FGF-2, and mixtures thereof, and 2. PIGF; and e) repeating steps b) through d) until there is a clinical indication of amelioration of the symptoms of chronic coronary artery disease in the patient, or until there is a contraindication to continued treatment. - View Dependent Claims (7, 8)
-
Specification